AIM ImmunoTech Reports $3.3 Million Net Loss in Q3 2025, Improved from Previous Year

AIM ImmunoTech Inc. reported a net loss of approximately $3.3 million for the third quarter of 2025, a decrease from a loss of $3.7 million in the same period of 2024. This represents an 11% reduction in losses, attributed primarily to a significant increase in interest and other income, which rose by $2.3 million due to a vendor agreement that forgave $3.04 million in previously billed legal fees. The company’s total revenues for the quarter were $26,000, down from $35,000 a year earlier, reflecting fluctuations in patient participation in its Ampligen Cost Recovery Program. The basic and diluted loss per share improved to $(1.57) from $(6.00) year-over-year.

For the nine months ending September 30, 2025, AIM reported a net loss of approximately $9.8 million, compared to $11.4 million for the same period in 2024, marking a 14% decrease. The reduction in losses was driven by lower general and administrative expenses, which fell by $3.7 million, and a decrease in research and development costs of $1.7 million. Total revenues for the nine-month period were $67,000, down from $125,000 in 2024, again primarily due to changes in patient participation. The weighted average number of shares outstanding increased significantly, contributing to a basic and diluted loss per share of $(8.18) compared to $(21.00) in the prior year.

Operationally, AIM ImmunoTech has been focusing on its flagship product, Ampligen, which is currently undergoing clinical trials for various applications, including pancreatic cancer and post-COVID conditions. The company has made strategic decisions to prioritize clinical activities based on the stage of development, with ongoing trials aimed at evaluating Ampligen's efficacy in combination with other therapies. As of September 30, 2025, AIM had 2,764,188 shares of common stock outstanding, a significant increase from 655,263 shares at the end of 2024, reflecting recent capital-raising efforts.

The company has also faced challenges regarding its compliance with the NYSE American listing requirements, particularly concerning stockholders' equity, which was reported at a deficit of approximately $6.1 million as of September 30, 2025. AIM submitted a plan to regain compliance by June 2026, which includes various capital formation initiatives. The company’s liquidity remains a concern, with cash and cash equivalents totaling approximately $2.4 million, down from $4 million at the end of 2024. AIM's management has indicated that if sufficient capital is not raised, it may need to limit business activities or face potential delisting from the exchange.

Looking ahead, AIM ImmunoTech is focused on advancing its clinical trials and exploring additional funding opportunities to support its operations. The company has entered into various agreements, including an equity distribution agreement with Maxim Group LLC, to facilitate capital raising efforts. AIM continues to evaluate its strategic options to enhance its market position and ensure the continued development of its therapeutic products.